Valuation: ME Therapeutics Holdings Inc.

Market Cap 7.6Cr 5.37Cr 4.77Cr 4.42Cr 4.03Cr 509.73Cr 7.72Cr 53Cr 21Cr 266Cr 20Cr 20Cr 847.96Cr P/E 2024
-51.7x
P/E 2025 -93.2x
Enterprise Value 7.46Cr 5.28Cr 4.69Cr 4.35Cr 3.96Cr 500.8Cr 7.58Cr 52Cr 20Cr 261.34Cr 20Cr 19Cr 833.1Cr EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
44.63%
Yield 2024 *
-
Yield 2025 -
1 week-35.71%
Current month-35.71%
1 month-56.10%
3 months-38.78%
6 months-28.00%
Current year-55.00%
1 week 1.51
Extreme 1.51
1.8
1 month 1.51
Extreme 1.51
2.8
Current year 0.79
Extreme 0.79
4.1
1 year 0.79
Extreme 0.79
8
3 years 0.05
Extreme 0.05
11
5 years 0.05
Extreme 0.05
11
10 years 0.05
Extreme 0.05
11
Manager TitleAgeSince
Chief Executive Officer 46 09/03/2023
Director of Finance/CFO 44 09/03/2023
Corporate Officer/Principal - 25/10/2024
Director TitleAgeSince
Director/Board Member 60 09/03/2023
Director/Board Member 46 09/03/2023
Director/Board Member 59 09/03/2023
Date Insider Type Main position Quantity % Market Cap. Importance
16/07/26 Option

Director

2,94,118 0.9788%
16/07/26 Sell

Director

2,94,118 0.9788%
16/07/26 Option

Chief Financial Officer

1,25,000 0.4160%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-35.71%-73.53%+185.71% 3.87Cr
-6.60%-8.56%+49.38%+63.51% 6.5TCr
+0.03%+5.56%+9.10%+69.05% 5.12TCr
-4.09%-0.11%+2.22%+53.15% 5.12TCr
-1.53%+2.70%+30.48%+34.12% 4.39TCr
-1.34%+4.12%+16.64%+115.13% 4.2TCr
-5.97%-6.22%+228.95%+454.22% 3.81TCr
+6.53%+8.02%+16.40%+53.41% 3.32TCr
-0.90%-10.49%+37.09%-3.70% 2.52TCr
-1.07%+2.33%+19.43%+9.98% 2.25TCr
Average -1.49%-0.32%+33.62%+103.46% 3.72TCr
Weighted average by Cap. -2.20%-0.50%+44.23%+96.54%

Financials

2024 2025
Net sales - -
Net income -12.95L -9L -8L -8L -7L -8.69Cr -13.15L -90.64L -35.54L -4.53Cr -34.35L -33.62L -14Cr -11.93L -8L -7L -7L -6L -8.01Cr -12.12L -83.54L -32.75L -4.18Cr -31.66L -30.98L -13Cr
Net Debt -14.97L -10.58L -9L -9L -8L -10Cr -15.21L -1.05Cr -41.09L -5.24Cr -39.71L -38.87L -17Cr -13.31L -9L -8L -8L -7L -8.93Cr -13.53L -93.2L -36.54L -4.66Cr -35.32L -34.57L -15Cr
Projected Income Statement - Annual - ME Therapeutics Holdings Inc.
Logo ME Therapeutics Holdings Inc.
ME Therapeutics Holdings Inc. is a preclinical stage biotechnology company involved in the discovery and development of novel immune oncology therapeutics targeting immune suppression in cancer. The Company’s focus is on overcoming the suppressive effects of a class of immune cells called myeloid cells to enhance anti-cancer immunity. The Company’s lead candidate is a novel high affinity antibody drug that targets a key protein involved in the generation of suppressive myeloid cells. In addition to its antibody drug candidate program, the Company is also developing a novel small molecule prodrug candidate designed to specifically target suppressive myeloid cells in the tumor environment. The Company has initiated design and testing of two new mRNA-based cancer therapeutic drug candidates.
Employees
-
Date Price Change Volume
15/26/15 CA$1.800 +12.50% 200
14/26/14 CA$1.600 -42.86% 4,020
  1. Stock Market
  2. Stocks
  3. METX Stock